The product, Fluorodeoxyglucose F‑18 (FDG), branded as FloDeg, is now being used at the Tzu Chi PIK Hospital in Jakarta, the Mitra Plumbon Hospital in Cirebon and the Mandaya Royal Puri Hospital in Tangerang, marking a new chapter in the country’s medical independence.

The rollout was made possible through the efforts of state-owned pharmaceutical company Bio Farma, which developed and manufactured FloDeg at its newly built cyclotron facility in Cikarang, West Java. The facility, inaugurated in 2024 by Health Minister Budi Gunadi Sadikin, has met national standards for pharmaceutical production (CPOB) and radiation safety protocols from BAPETEN.

“The initial distribution of FloDeg is proof of our commitment to strengthening national self-sufficiency in cancer diagnostics,” said Yuliana Indriati, Director of Business Development at Bio Farma. “This is a historic moment, as Indonesia is for the first time producing and distributing its own radiopharmaceutical.”

Medical professionals at Tzu Chi Hospital praised the quality and timeliness of the delivery. “We are pleased with FloDeg’s performance and responsiveness. It opens the door for long-term collaboration,” said Dr. Suriyanto, the hospital’s medical director.

The introduction of FloDeg is seen as a critical step in reducing Indonesia’s dependency on imported diagnostic tools, while also laying the groundwork for future theragnostic product development. With strategic government backing, the country is positioning itself as a serious player in nuclear medicine innovation in Southeast Asia.

Popular

Early school a new burden

Bali flights canceled after Lewotobi Laki-laki volcano eruption

Mt Lewotobi Laki-Laki’s alert status raised to highest level